CN101327310B - Chinese medicinal composition for treating hyperlipemia and preparation thereof - Google Patents
Chinese medicinal composition for treating hyperlipemia and preparation thereof Download PDFInfo
- Publication number
- CN101327310B CN101327310B CN200810110766XA CN200810110766A CN101327310B CN 101327310 B CN101327310 B CN 101327310B CN 200810110766X A CN200810110766X A CN 200810110766XA CN 200810110766 A CN200810110766 A CN 200810110766A CN 101327310 B CN101327310 B CN 101327310B
- Authority
- CN
- China
- Prior art keywords
- rhizoma
- chinese medicine
- portions
- weight
- blood
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 201000005577 familial hyperlipidemia Diseases 0.000 title claims description 35
- 239000000203 mixture Substances 0.000 title claims description 24
- 239000003814 drug Substances 0.000 claims abstract description 87
- 238000011282 treatment Methods 0.000 claims abstract description 61
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 52
- 229940079593 drug Drugs 0.000 claims description 32
- 238000000034 method Methods 0.000 claims description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 27
- 239000000341 volatile oil Substances 0.000 claims description 24
- 239000008187 granular material Substances 0.000 claims description 19
- 210000000582 semen Anatomy 0.000 claims description 17
- 239000007864 aqueous solution Substances 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000000284 extract Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 238000010992 reflux Methods 0.000 claims description 6
- 239000007921 spray Substances 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 4
- 238000002481 ethanol extraction Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000007493 shaping process Methods 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 238000004064 recycling Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 abstract description 68
- 210000004369 blood Anatomy 0.000 abstract description 65
- 230000000694 effects Effects 0.000 abstract description 57
- 210000002966 serum Anatomy 0.000 abstract description 14
- 150000002632 lipids Chemical class 0.000 abstract description 13
- 239000002994 raw material Substances 0.000 abstract description 6
- 231100000957 no side effect Toxicity 0.000 abstract description 5
- 206010033557 Palpitations Diseases 0.000 abstract description 4
- 206010008479 Chest Pain Diseases 0.000 abstract description 3
- 206010019233 Headaches Diseases 0.000 abstract description 3
- 208000002173 dizziness Diseases 0.000 abstract description 3
- 231100000869 headache Toxicity 0.000 abstract description 3
- 240000007164 Salvia officinalis Species 0.000 abstract description 2
- 235000005412 red sage Nutrition 0.000 abstract description 2
- 244000144730 Amygdalus persica Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 abstract 1
- 235000003392 Curcuma domestica Nutrition 0.000 abstract 1
- 240000009138 Curcuma zedoaria Species 0.000 abstract 1
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract 1
- 241000212322 Levisticum officinale Species 0.000 abstract 1
- 244000202052 Poncirus trifoliata Species 0.000 abstract 1
- 235000000404 Poncirus trifoliata Nutrition 0.000 abstract 1
- 235000006040 Prunus persica var persica Nutrition 0.000 abstract 1
- 244000086363 Pterocarpus indicus Species 0.000 abstract 1
- 235000009984 Pterocarpus indicus Nutrition 0.000 abstract 1
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 241000233932 Sparganium Species 0.000 abstract 1
- 230000007012 clinical effect Effects 0.000 abstract 1
- 235000003373 curcuma longa Nutrition 0.000 abstract 1
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract 1
- 239000001645 levisticum officinale Substances 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 235000013976 turmeric Nutrition 0.000 abstract 1
- 235000019509 white turmeric Nutrition 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 60
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 37
- 239000003795 chemical substances by application Substances 0.000 description 31
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 29
- 208000024891 symptom Diseases 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 230000010354 integration Effects 0.000 description 23
- 210000002105 tongue Anatomy 0.000 description 23
- 229960004756 ethanol Drugs 0.000 description 19
- 108010023302 HDL Cholesterol Proteins 0.000 description 18
- 102000015779 HDL Lipoproteins Human genes 0.000 description 17
- 241000283973 Oryctolagus cuniculus Species 0.000 description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 16
- 235000012000 cholesterol Nutrition 0.000 description 15
- 238000009826 distribution Methods 0.000 description 12
- 235000013305 food Nutrition 0.000 description 12
- 239000003153 chemical reaction reagent Substances 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 238000000605 extraction Methods 0.000 description 10
- 238000002156 mixing Methods 0.000 description 10
- 108010010234 HDL Lipoproteins Proteins 0.000 description 8
- 210000001367 artery Anatomy 0.000 description 8
- 210000003462 vein Anatomy 0.000 description 8
- 241000282894 Sus scrofa domesticus Species 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000001737 promoting effect Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 229920002307 Dextran Polymers 0.000 description 6
- 238000001514 detection method Methods 0.000 description 6
- 210000002969 egg yolk Anatomy 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 210000000232 gallbladder Anatomy 0.000 description 6
- 230000007246 mechanism Effects 0.000 description 6
- MFZCIDXOLLEMOO-GYSGTQPESA-N myo-inositol hexanicotinate Chemical compound O([C@H]1[C@@H]([C@H]([C@@H](OC(=O)C=2C=NC=CC=2)[C@@H](OC(=O)C=2C=NC=CC=2)[C@@H]1OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)OC(=O)C=1C=NC=CC=1)C(=O)C1=CC=CN=C1 MFZCIDXOLLEMOO-GYSGTQPESA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 241000700159 Rattus Species 0.000 description 5
- 230000017531 blood circulation Effects 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 210000004185 liver Anatomy 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 239000008588 xue-zhi-ning Substances 0.000 description 5
- 102000008946 Fibrinogen Human genes 0.000 description 4
- 108010049003 Fibrinogen Proteins 0.000 description 4
- 206010062717 Increased upper airway secretion Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 230000004087 circulation Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- -1 drying Substances 0.000 description 4
- 229940012952 fibrinogen Drugs 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000004089 microcirculation Effects 0.000 description 4
- 208000026435 phlegm Diseases 0.000 description 4
- 230000003449 preventive effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 210000002784 stomach Anatomy 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 206010053567 Coagulopathies Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KNAHARQHSZJURB-UHFFFAOYSA-N Propylthiouracile Chemical compound CCCC1=CC(=O)NC(=S)N1 KNAHARQHSZJURB-UHFFFAOYSA-N 0.000 description 3
- 208000001431 Psychomotor Agitation Diseases 0.000 description 3
- 206010038743 Restlessness Diseases 0.000 description 3
- 210000000709 aorta Anatomy 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 230000035602 clotting Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 208000006750 hematuria Diseases 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000012856 packing Methods 0.000 description 3
- 230000003285 pharmacodynamic effect Effects 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 208000037920 primary disease Diseases 0.000 description 3
- 229960002662 propylthiouracil Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- 241000208340 Araliaceae Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 206010061245 Internal injury Diseases 0.000 description 2
- 241000283977 Oryctolagus Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- AIGAZQPHXLWMOJ-UHFFFAOYSA-N Tanshinone I Chemical compound C1=CC2=C(C)C=CC=C2C(C(=O)C2=O)=C1C1=C2C(C)=CO1 AIGAZQPHXLWMOJ-UHFFFAOYSA-N 0.000 description 2
- FINHMKGKINIASC-UHFFFAOYSA-N Tetramethylpyrazine Chemical compound CC1=NC(C)=C(C)N=C1C FINHMKGKINIASC-UHFFFAOYSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 238000007824 enzymatic assay Methods 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960005436 inositol nicotinate Drugs 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 231100000915 pathological change Toxicity 0.000 description 2
- 230000036285 pathological change Effects 0.000 description 2
- 235000019353 potassium silicate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- NTHWMYGWWRZVTN-UHFFFAOYSA-N sodium silicate Chemical compound [Na+].[Na+].[O-][Si]([O-])=O NTHWMYGWWRZVTN-UHFFFAOYSA-N 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- 239000011800 void material Substances 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 206010065559 Cerebral arteriosclerosis Diseases 0.000 description 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 1
- 206010008190 Cerebrovascular accident Diseases 0.000 description 1
- 206010010144 Completed suicide Diseases 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 241001269238 Data Species 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 241000628997 Flos Species 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010062713 Haemorrhagic diathesis Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 208000035286 Spontaneous Remission Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 229930183118 Tanshinone Natural products 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000489 anti-atherogenic effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 230000003143 atherosclerotic effect Effects 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003433 contraceptive agent Substances 0.000 description 1
- 230000002254 contraceptive effect Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 229960000935 dehydrated alcohol Drugs 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 238000003748 differential diagnosis Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003414 extremity Anatomy 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002695 general anesthesia Methods 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000013210 hematogenous Diseases 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000031169 hemorrhagic disease Diseases 0.000 description 1
- 230000000055 hyoplipidemic effect Effects 0.000 description 1
- 208000003532 hypothyroidism Diseases 0.000 description 1
- 230000002989 hypothyroidism Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 201000005851 intracranial arteriosclerosis Diseases 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000003907 kidney function Effects 0.000 description 1
- 238000009592 kidney function test Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009533 lab test Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000010271 massa medicata fermentata Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 125000001484 phenothiazinyl group Chemical class C1(=CC=CC=2SC3=CC=CC=C3NC12)* 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108700022737 rat Fat1 Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
Description
Factor level | A (amount of water) (doubly) | B (decoction number of times) (inferior) | C fry in shallow oil and hour boil the time (hour) |
1 | 12 (7,5 or 5,4,3) | 2 | 2 (1,1 or 1,0.5,0.5) |
2 | 14 (8,6 or 6,4,4) | 3 | (2.5 1,5,1 or 1.1,0.5) |
3 | 16 (9,7 or 7,5,4) | 2 | 3 (2,1 or 1,1,1) |
Sample number into spectrum | Radix Salviae Miltiorrhizae | Rhizoma Chuanxiong | Semen Persicae | Lignum Dalbergiae Odoriferae | Rhizoma sparganic | Rhizoma Curcumae | Fructus Aurantii | Radix Et Rhizoma Rhei |
1 | 300 | 200 | 200 | 130 | 200 | 200 | 130 | 60 |
2 | 334 | 250 | 250 | 167 | 250 | 250 | 167 | 84 |
3 | 360 | 300 | 300 | 180 | 300 | 300 | 180 | 100 |
4 | 350 | 280 | 280 | 160 | 280 | 280 | 160 | 90 |
5 | 340 | 290 | 290 | 175 | 295 | 295 | 175 | 95 |
6 | 355 | 265 | 265 | 130 | 300 | 300 | 175 | 60 |
7 | 330 | 245 | 245 | 160 | 250 | 250 | 160 | 80 |
8 | 334 | 250 | 250 | 160 | 245 | 245 | 167 | 84 |
9 | 365 | 305 | 305 | 185 | 305 | 305 | 185 | 105 |
10 | 375 | 315 | 315 | 195 | 315 | 320 | 190 | 110 |
11 | 390 | 320 | 320 | 200 | 320 | 320 | 200 | 115 |
12 | 360 | 305 | 305 | 185 | 300 | 300 | 170 | 87 |
13 | 400 | 220 | 220 | 120 | 150 | 150 | 125 | 45 |
14 | 295 | 195 | 195 | 125 | 195 | 195 | 125 | 55 |
15 | 280 | 185 | 185 | 120 | 180 | 180 | 120 | 50 |
16 | 270 | 200 | 220 | 185 | 195 | 195 | 130 | 80 |
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810110766XA CN101327310B (en) | 2008-05-29 | 2008-05-29 | Chinese medicinal composition for treating hyperlipemia and preparation thereof |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810110766XA CN101327310B (en) | 2008-05-29 | 2008-05-29 | Chinese medicinal composition for treating hyperlipemia and preparation thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101327310A CN101327310A (en) | 2008-12-24 |
CN101327310B true CN101327310B (en) | 2011-08-24 |
Family
ID=40203462
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200810110766XA Expired - Fee Related CN101327310B (en) | 2008-05-29 | 2008-05-29 | Chinese medicinal composition for treating hyperlipemia and preparation thereof |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101327310B (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN107715062A (en) * | 2017-11-07 | 2018-02-23 | 山东省中医药研究院 | One kind is used to treat cardiovascular artery sclerosis Chinese medicine |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094624A (en) * | 1993-05-08 | 1994-11-09 | 李明复 | Quick-acting fat-lowering spirit Chinese medicine |
-
2008
- 2008-05-29 CN CN200810110766XA patent/CN101327310B/en not_active Expired - Fee Related
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1094624A (en) * | 1993-05-08 | 1994-11-09 | 李明复 | Quick-acting fat-lowering spirit Chinese medicine |
Also Published As
Publication number | Publication date |
---|---|
CN101327310A (en) | 2008-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101485796A (en) | Chinese medicinal composition for treating insomnia as well as preparation method and quality control method thereof | |
CN101390887A (en) | Medicine composition of Panax notoginseng saponins | |
CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
CN103989996B (en) | It is a kind of to treat Chinese medicine composition of diabetes and preparation method thereof | |
CN101327310B (en) | Chinese medicinal composition for treating hyperlipemia and preparation thereof | |
CN111195310A (en) | Traditional Chinese medicine composition for treating hyperlipidemia | |
CN101628104A (en) | Traditional Chinese medicine composition used for treating melancholia | |
CN102652819B (en) | Fuyankang dispersible tablet and preparation method thereof | |
US7381430B2 (en) | Pharmaceutical composition comprising a combination of Chinese traditional medicines | |
CN108578487A (en) | The pharmaceutical composition and preparation and application and preparation for the treatment of psoriasis vulgaris | |
CN100409880C (en) | Mongolian medicine Baolier for treating hyperlipemia and method for preparing same | |
CN105055967B (en) | A kind of complex health care product and preparation method with auxiliary hyperglycemic function | |
CN113599447A (en) | Traditional Chinese medicine composition for improving phlegm-dampness constitution and preparation method and application thereof | |
CN105833055A (en) | Traditional Chinese medicine composition for treating hypertension, hyperlipidemia and hyperglycemia and preparing method and application thereof | |
CN102988779A (en) | Chinese medicine composition for treating hypertensive nephropathy and preparation method and application of Chinese medicine composition | |
CN106109951A (en) | Prevent and treat medicine of hyperglycemia, hyperlipidemia, hypertension and preparation method thereof | |
CN104800662A (en) | Traditional Chinese medicine for treating senile heart failure and preparation method thereof | |
CN101947299B (en) | Medicinal composition for treating coronary heart disease | |
CN105194355A (en) | Traditional Chinese medicine preparation for treating primary hypertension | |
CN103263581A (en) | Shuangshen capsule for reducing blood sugar | |
CN104645246B (en) | A kind of pharmaceutical preparation depressed for Menopause | |
CN109620913A (en) | It is a kind of to prevent and/or treat fat, hyperglycemia composition | |
CN103784893A (en) | Medicine for treating sequela of cerebra apoplexy | |
CN108478706A (en) | It is a kind of to protect cardiovascular composition and preparation method thereof | |
CN102078367B (en) | Use of aidi preparation in preparation of medicaments for treating multiple organ dysfunction syndrome in elderly |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: JILIN AODONG GROUP DALIAN PHARMACEUTICAL CO., LTD. Free format text: FORMER OWNER: LIU DESHENG Effective date: 20140612 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20140612 Address after: 116043, Lushun North Road (three Jian section), Lushunkou District, Liaoning, Dalian, 477 Patentee after: Jilin Aodong Group Dalian Pharmaceutical Co.,Ltd. Address before: 116043 No. 65-604, four street, Dalian, Liaoning Patentee before: Liu Desheng |
|
ASS | Succession or assignment of patent right |
Owner name: DALIAN SHENGHONG MEDICINE CO., LTD. Free format text: FORMER OWNER: JILIN AODONG GROUP DALIAN PHARMACEUTICAL CO., LTD. Effective date: 20150421 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 116043 DALIAN, LIAONING PROVINCE TO: 116045 DALIAN, LIAONING PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20150421 Address after: 210 Liaoning, Dalian, Lushunkou District, Tieshan street, No. 116045 innovation road, room 1 Patentee after: Dalian Shenghong Medicine Co., Ltd. Address before: 116043, Lushun North Road (three Jian section), Lushunkou District, Liaoning, Dalian, 477 Patentee before: Jilin Aodong Group Dalian Pharmaceutical Co.,Ltd. |
|
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20110824 Termination date: 20160529 |